“Global Desmoid Tumors Market Is Expected to Grow at a CAGR 4.5% During the Forecast Period Of 2017-2023”.
Desmoid Tumors Market Overview
Desmoid tumors are the benign fibrous growths which usually develops in the fibrous tissue of the body, commonly in the arms, legs or midsection, and sometimes in the head and neck. According to the U.S National Library of Medicine, Desmoid tumors are very rare as the rate of occurrence is estimated to be 1 to 2 per 500,000 people worldwide. It is also stated that nearly 900 to 1,500 new cases are registered per year in the United States.
Tumors associated with familial adenomatous polyposis (FAP) are less common than sporadic desmoid tumors. On the molecular level, desmoid tumor is characterized by one of the two mutations in the gene i.e. mutations in the adenomatous polyposis coli (APC) gene, or in the β-catenin gene, CTNNB1. During diagnostic procedures CTNNB1 mutation is detected, especially, when pathological differential diagnosis is difficult.
Request a Free Sample at https://www.marketresearchfuture.com/sample_request/4859
The symptoms of desmoid tumors include a painless swelling or lump, pain and obstruction of the bowels, limping, pain caused by compressed nerves or muscles, and others. For the diagnosis of desmoid tumor there are many non-invasive methods available to detect desmoid tumor which include ultrasound, MRI scan, and CT scan. The actual diagnosis of this tumor can be made only after examining a small piece of the tumor by a trained pathologist.
High cost of treatment & management of desmoid tumors and related disorders, and lack of infrastructure in middle- and low-income countries may hamper the growth of the market.
Competitive Analysis:
Some of key the players in the Desmoid Tumors Market are
- Amgen Inc.
- Novartis AG
- Abbott Laboratories
- Bayer AG
- AbbVie Inc.
- Beckman Coulter Inc.
- Stryker Corporation
- Debiopharm Group
- Hoffmann-La Roche Ltd
- and others.
Desmoid Tumors Market Segmental Analysis:
The desmoid tumors market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, market is segmented into biopsy, electron microscopic examination, immunohistochemical analysis, others
On the basis of treatment, market is classified into surgery, radiation therapy, anti-inflammatory medication, hormone therapy, chemotherapy, novel molecular-targeted therapy, others. Novel molecular-targeted therapy is further segmented into gleevec based therapy, and sorafenib based therapy
On the basis of end-user, market is segmented into hospital, clinics, and others.
Brows Complete Detailed Premium Research Report at https://www.marketresearchfuture.com/reports/desmoid-tumors-market-4859
Desmoid Tumors Market Regional Analysis:
The Americas dominate the desmoid tumors market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), it is found that out of total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States. Furthermore, increasing participation of bigger players and new marketers towards advancement in treatment approaches have also attracted a great deal of attention.
Europe holds the second position in the desmoid tumors market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region.
Asia Pacific is the fastest growing desmoid tumors market owing to the huge patient pool and developing healthcare technology.
The Middle East & Africa has the lowest market for desmoid tumors market due to lack of technical knowledge and poor medical facilities.
LIST OF TABLES
Table 1 Desmoid Tumor Industry Synopsis, 2017 – 2023
Table 2 Desmoid Tumor Market Estimates And Forecast, 2017 – 2023, (USD Million)
Table 3 Desmoid Tumor Market By Region, 2017 – 2023, (USD Million)
Table 4 Desmoid Tumor Market By Diagnosis, 2017 – 2023, (USD Million)
Table 5 Desmoid Tumor Market By Treatment, 2017 – 2023, (USD Million)
Table 6 Desmoid Tumor Market By End Users, 2017 – 2023, (USD Million)
Table 7 North America Desmoid Tumor Market By Diagnosis, 2017 – 2023, (USD Million)
…To be Continued.
Get an Exclusive Discount at https://www.marketresearchfuture.com/check-discount/4859
Contact Market Research Future:
Comments
Post a Comment